美因基因
mega genomics

Mega Genomics Limited
美因基因有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6667)

INSIDE INFORMATION
(1) DELAY IN PUBLICATION OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024;
(2) POSTPONEMENT OF THE BOARD MEETING;
AND
(3) SUSPENSION OF TRADING

This announcement is made by Mega Genomics Limited (the "**Company**" together with its subsidiaries, collectively referred to as the "**Group**") pursuant to the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

Reference is made to the announcement of the Company dated 19 March 2025 in relation to the meeting of the board (the "**Board**") of the directors (the "**Director(s)**") scheduled to be held on 31 March 2025 for the purpose of, among other matters, considering and approving the annual results of the Group for year ended 31 December 2024 (the "**2024 Annual Results**").

DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS

Pursuant to Rule 13.49 of the Listing Rules, the Company is required to publish an announcement for the 2024 Annual Results on a date not later than three months after the financial year, namely, on or before 31 March 2025. The Board would like to inform shareholders and potential investors of the Company that, the Company has provided the relevant information to the auditors, and the auditors expressed that more time is needed and further information from the Company is required to further determine the rationale of revenue recognition from advance receipts for genetic testing kits and the nature of certain promotion fees and advance payments to promoters.

In view of the above circumstances, the auditors proposed that more time is needed with additional costs to be incurred to proceed with the next step of additional work. It was also mentioned that the Company may consider the change of auditors, or consider the option of conducting an independent investigation into the above transactions. As such, there will be a delay in the publication of the 2024 Annual Results. The delay in publishing the 2024 Annual Results will constitute a non-compliance with Rule 13.46(2)(a) of the Listing Rules.

The Company is working closely with its auditors with a view to resolving the outstanding matters and completing the audit of the 2024 Annual Results as soon as practicable. The Company will use its best endeavours to ensure that the 2024 Annual Results will be published as soon as practicable, and will provide the latest updates thereto.

POSTPONEMENT OF THE BOARD MEETING

As it is anticipated that the 2024 Annual Results will not be available for publication by 31 March 2025, the meeting of the Board for the purpose of, among other matters, considering and approving the 2024 Annual Results and its publication, will be postponed until further notice.

SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on 1 April 2025 pending the release of the 2024 Annual Results. Further announcement(s) will be made by the Company in relation to the publication of the 2024 Annual Results and/or further Board meeting for the 2024 Annual Results as and when appropriate and in accordance with the Listing Rules.

By Order of the Board
Mega Genomics Limited
LIN Lin
Executive Director and Chairperson

Hong Kong, 1 April 2025

As of the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.

* *For identification purpose only*